pre-IPO PHARMA

COMPANY OVERVIEW

Philogen is a Swiss-Italian integrated biotechnology company founded in 1996, with the mission to develop innovative biopharmaceuticals for the treatment of angiogenesis-related disorders. Angiogenesis, i.e. the formation of new blood vessels, is a characteristic feature of many severe pathologies such as cancer, rheumatoid arthritis and age-related macular degeneration.


LOCATION

  • Sovicille, , Italy
  • Monteriggioni, , Italy

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://www.philogen.com/en/


    CAREER WEBSITE

    https://www.philogen.com/en/careers/


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    May 30, 2023

    Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand USA - English USA - English APAC - English USA - español USA - Deutsch USA - Français


    Dec 1, 2022

    Philogen Provides Corporate Update


    Jan 13, 2021

    Philogen Announces the Completion of a Second Interim Analysis of Its Phase III Clinical Program With Nidlegy for the Treatment of Melanoma


    Oct 8, 2020

    Philogen Announces Publication of Malignant Brain Tumor Study Results in Science Translational Medicine


    Jun 26, 2020

    Philogen Received Clinical Trial Authorisation With Nidlegy in Nonmelanoma Skin Cancer English English


    For More Press Releases


    Google Analytics Alternative